EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment

Zibo Zhao iD, Yuki Aoi, Cassandra N Philips iD, Khyati A Meghani iD, Sarah R Gold iD, Yanni Yu iD, Luke St John iD, Jun Qian iD, Jacob M Zeidner iD, Joshua J Meeks iD, Ali Shilatifard

Proceedings of the National Academy of Sciences · 26.12.2023 · 120 (52)

DOI: 10.1073/pnas.2310063120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 19.12.2023. Verfasst von Zibo Zhao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611. Hauptthemen laut MEDLINE: Histones, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BLRD VA, NCI NIH HHS, HHS | NIH | NCI | Center for Biomedical Informatics and Information Technology, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer genome sequencing consortiums have recently catalogued an abundance of somatic mutations, across a wide range of human cancers, in the chromatin-modifying enzymes that regulate gene expression. Defining the molecular mechanisms underlying the potentially oncogenic functions of these epigenetic mutations could serve as the basis for precision medicine approaches to cancer therapy. MLL4 encoded by the KMT2D gene highly mutated in a large number of human cancers, is a key histone lysine monomethyltransferase within the Complex of Proteins Associated with Set1 (COMPASS) family that regulates gene expression through enhancer function, potentially functioning as a tumor suppressor. We report that the KMT2D mutations which cause MLL4 protein truncation also alter MLL4’s subcellular localization, resulting in loss-of-function in the nucleus and gain-of-function in the cytoplasm. We demonstrate that isogenic correction of KMT2D truncation mutation rescues the aberrant localization phenotype and restores multiple regulatory functions of MLL4, including COMPASS integrity/stabilization, histone H3K4 mono-methylation, enhancer activation, and therefore transcriptional regulation. Moreover, isogenic correction diminishes the sensitivity of KMT2D -mutated cancer cells to targeted metabolic inhibition. Using immunohistochemistry, we identified that cytoplasmic MLL4 is unique to the tissue of bladder cancer patients with KMT2D truncation mutations. Using a preclinical carcinogen model of bladder cancer in mouse, we demonstrate that truncated cytoplasmic MLL4 predicts response to targeted metabolic inhibition therapy for bladder cancer and could be developed as a biomarker for KMT2D -mutated cancers. We also highlight the broader potential for prognosis, patient stratification and treatment decision-making based on KMT2D mutation status in MLL4 truncation-relevant diseases, including human cancers and Kabuki Syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HistonesUrinary Bladder NeoplasmsHumansAnimalsMiceCytoplasmPrognosisHistone-Lysine N-MethyltransferaseMutation

Stichwörter der Autor:innen

cancer biomarkerchromatin modifiersepigeneticsmutationtreatment

Substanzen

HistonesHistone-Lysine N-MethyltransferaseMLL4 protein, humanMLL4 protein, mouse

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611.
  • Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611.
  • Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.

ORCID-Profile: Zibo Zhao, Cassandra N Philips, Khyati A Meghani, Sarah R Gold, Yanni Yu, Luke St John, Jun Qian, Jacob M Zeidner, Joshua J Meeks

Förderung

  • BLRD VA
  • NCI NIH HHS
  • HHS | NIH | NCI | Center for Biomedical Informatics and Information Technology, National Cancer Institute

Zitieren

APA

Zhao, Z., Aoi, Y., Philips, C. N., Meghani, K. A., Gold, S. R., Yu, Y., John, L. S., Qian, J., Zeidner, J. M., Meeks, J. J., & Shilatifard, A. (2023). Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment. Proceedings of the National Academy of Sciences, 120(52). https://doi.org/10.1073/pnas.2310063120

Vancouver

Zhao Z, Aoi Y, Philips CN, Meghani KA, Gold SR, Yu Y, et al. Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment. Proceedings of the National Academy of Sciences. 2023;120(52). doi:10.1073/pnas.2310063120

BibTeX
@article{Zhao2023,
  author = {Zhao, Zibo and Aoi, Yuki and Philips, Cassandra N and Meghani, Khyati A and Gold, Sarah R and Yu, Yanni and John, Luke St and Qian, Jun and Zeidner, Jacob M and Meeks, Joshua J and Shilatifard, Ali},
  title = {Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  volume = {120},
  number = {52},
  doi = {10.1073/pnas.2310063120}
}
Kostenlos starten →